Leadership Overview
PCI Pharma Services has 8 executives leading key functions including operations, finance, information technology, clinical quality, and manufacturing.
Focused on delivering integrated healthcare solutions, PCI Pharma Services advances global patient outcomes through comprehensive analytical, manufacturing, and supply chain expertise across North American and European markets.
Focused on delivering integrated healthcare solutions, PCI Pharma Services advances global patient outcomes through comprehensive analytical, manufacturing, and supply chain expertise across North American and European markets.
Leadership Roles at PCI Pharma Services
Tom DeWeerdt - Chief Financial Officer
Tom DeWeerdt, the Chief Financial Officer at PCI Pharma Services, manages the fiscal health and capital allocation strategies for the global organization. Overseeing financial planning, reporting, and risk management, the Chief Financial Officer ensures the company maintains a robust balance sheet to support ongoing expansion. This leadership role involves evaluating investment opportunities in formulation development and manufacturing infrastructure. By optimizing capital structure, Tom DeWeerdt directly impacts the company's capacity for innovation and market growth. The Chief Financial Officer collaborates with executive leadership to align financial goals with the strategic objectives of the healthcare service portfolio. Through rigorous oversight of financial performance, DeWeerdt secures the necessary resources for sustained development. This commitment to fiscal discipline supports the overarching mission of providing integrated pharmaceutical services, ensuring that the organization remains financially agile while navigating the complexities of the global healthcare market and maintaining long-term value for stakeholders.
Brad Payne - Chief Operating Officer
Brad Payne, the Chief Operating Officer at PCI Pharma Services, directs the internal scaling and operational efficiency of the global manufacturing network. Overseeing the integration of analytical services and commercial packaging, the Chief Operating Officer ensures seamless execution across all facilities. This leadership role involves optimizing supply chain management to meet rigorous healthcare industry standards. By streamlining production workflows, Brad Payne directly impacts the company's ability to deliver clinical trial supplies with precision. The Chief Operating Officer maintains alignment with the Board to drive long-term operational excellence. Through the management of complex distribution logistics, Payne secures the reliability of the entire service portfolio. This focus on operational rigor supports the broader mission of providing high-quality pharmaceutical solutions to clients worldwide, ensuring that every manufacturing process adheres to strict regulatory requirements while maximizing output capacity and maintaining consistent quality benchmarks across the enterprise.
Laila Rubi - Chief Operating Officer, Clinical Quality Documents
Laila Rubi, the Chief Operating Officer, Clinical Quality Documents at PCI Pharma Services, governs the regulatory compliance and quality documentation standards for clinical trial operations. Overseeing the rigorous validation of quality processes, the Chief Operating Officer, Clinical Quality Documents ensures that all documentation meets international healthcare standards. This leadership role involves managing the intersection of clinical trial supply and regulatory requirements to guarantee patient safety. By standardizing quality protocols, Laila Rubi directly impacts the reliability of the company's clinical service offerings. The Chief Operating Officer, Clinical Quality Documents collaborates with manufacturing and analytical teams to maintain a culture of compliance. Through the meticulous oversight of quality documentation, Rubi secures the trust of global healthcare partners. This dedication to quality assurance supports the company's mission by providing a foundation of regulatory excellence, ensuring that every clinical project adheres to the highest industry benchmarks while facilitating smooth and efficient trial execution.
Halley Liu - President
Halley Liu, the President at PCI Pharma Services, drives the overarching strategic vision and market positioning for the global healthcare provider. Overseeing the alignment of diverse service lines, the President ensures that analytical services, manufacturing, and distribution work in concert to meet client needs. This leadership role involves fostering growth across North American and European markets through targeted business development. By championing innovation in pharmaceutical services, Halley Liu directly impacts the company's ability to capture new market share. The President coordinates with the executive team to execute long-term objectives and maintain operational excellence. Through the cultivation of strategic partnerships, Liu secures the company's status as a leader in the global healthcare industry. This focus on strategic growth supports the mission of providing integrated, full-service solutions, ensuring that the organization remains responsive to the evolving demands of the pharmaceutical sector while delivering consistent value to clients and stakeholders.
Michelle Logan - President, Development & Manufacturing
Michelle Logan, the President, Development & Manufacturing at PCI Pharma Services, leads the formulation development and commercial manufacturing divisions. Overseeing the transition from early-stage development to full-scale production, the President, Development & Manufacturing ensures that technical processes meet client specifications. This leadership role involves managing the technical teams responsible for complex pharmaceutical formulations and manufacturing workflows. By optimizing production capabilities, Michelle Logan directly impacts the company's ability to scale operations for global clients. The President, Development & Manufacturing collaborates with analytical and supply chain leaders to ensure project success from inception to delivery. Through the oversight of manufacturing excellence, Logan secures the company's reputation for high-quality production. This focus on technical development supports the mission of providing comprehensive healthcare solutions, ensuring that the organization remains at the forefront of pharmaceutical manufacturing innovation while maintaining strict adherence to quality and safety standards across all production facilities.
Brian Keesee - President, Clinical Trial Services
Brian Keesee, the President, Clinical Trial Services at PCI Pharma Services, manages the end-to-end delivery of clinical trial supply solutions. Overseeing the storage, distribution, and logistics of clinical materials, the President, Clinical Trial Services ensures that global trials receive necessary supplies on time. This leadership role involves coordinating complex supply chain networks to support diverse clinical research requirements. By streamlining clinical logistics, Brian Keesee directly impacts the speed and efficiency of global drug development programs. The President, Clinical Trial Services works with internal teams to ensure that storage and distribution protocols meet the highest regulatory standards. Through the management of clinical trial operations, Keesee secures the reliability of the company's service offerings. This focus on clinical excellence supports the mission of providing integrated healthcare solutions, ensuring that the organization remains a trusted partner for pharmaceutical companies conducting critical research across international markets.
Yann Ghafourzadeh - President, Commercial Packaging Technology
Yann Ghafourzadeh, the President, Commercial Packaging Technology at PCI Pharma Services, directs the innovation and implementation of advanced packaging solutions for commercial pharmaceutical products. Overseeing the design and execution of specialized packaging technologies, the President, Commercial Packaging Technology ensures that products are prepared for market with maximum efficiency and compliance. This leadership role involves integrating new packaging machinery and processes to meet the evolving needs of the healthcare industry. By advancing packaging capabilities, Yann Ghafourzadeh directly impacts the company's ability to provide high-quality, market-ready solutions. The President, Commercial Packaging Technology collaborates with manufacturing and supply chain teams to ensure seamless integration of packaging services into the broader product lifecycle. Through the oversight of packaging technology, Ghafourzadeh secures the company's position as a leader in commercial pharmaceutical services. This focus on packaging innovation supports the mission of providing integrated healthcare solutions, ensuring that every product meets the highest standards of safety, integrity, and presentation.
Edward DePrimo - Chief Information Officer
Edward DePrimo, the Chief Information Officer at PCI Pharma Services, architects the digital infrastructure and cybersecurity frameworks supporting global operations. Overseeing the implementation of advanced data systems, the Chief Information Officer ensures the integrity of clinical trial supply tracking and analytical data. This leadership role involves driving digital transformation to enhance connectivity between manufacturing sites and client platforms. By modernizing information technology, Edward DePrimo directly impacts the efficiency of supply chain management and distribution services. The Chief Information Officer works closely with other C-suite leaders to integrate secure, scalable technology solutions across the enterprise. Through the deployment of robust data analytics, DePrimo supports informed decision-making and operational transparency. This focus on technological advancement enables the company to maintain a competitive edge in the pharmaceutical industry, ensuring that all digital assets remain protected while facilitating seamless communication and data exchange across the global network of facilities.
Explore Leadership Teams in Manufacturing
USV Private Limited is an Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai, India. USV Limited was established in 1961.
Company Leadership
SY
GJ
Kyowa Kirin is a global specialty pharmaceutical company focused on antibody research and engineering to address the needs of patients and society across multiple therapeutic areas, including Nephrology, Oncology, Immunology/Allergy and Neurology. They are headquartered in Tokyo, Japan.
Company Leadership SS
JC
CS
KS
OrchidPharma Ltd is a vertically integrated pharmaceutical company with established research, manufacturing, and marketing capabilities across multiple therapeutic domains in healthcare. The company aims to build a sustainable organizational ecosystem that motivates individuals to achieve new heights and discover growth avenues. OrchidPharma is driven by values such as innovation and corporate social responsibility, alongside its strategic goals. Its intended clients include healthcare providers and organizations seeking comprehensive pharmaceutical solutions.
Company Leadership KP
NA
PP
MS
Soft gelatin capsule products, liquid preparations, medicinal plasters, ointments, and creams are produced at the Gunung Putri Plant. In producing these products, Gunung Putri Plant implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018 and ISO 22000:2018 certificates. Meanwhile, sterile injection products and solid preparations in the form of tablets and capsules are produced at the Citeureup Plant. The Citeureup Plant also implements an Integrated Management System and has obtained ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, and SNI ISO/IEC 17025:2017 certificates. In running the Toll Manufacturing business, Darya-Varia collaborates with an affiliated company, PT Medifarma Laboratories, at the Cimanggis Depok Plant. The Company has been trusted by local business partners and both for the domestic and international markets for the Export & Toll Manufacturing business and conducts technology transfer, lab and pilot trials, stability studies, procurement of raw materials and packaging, and commercial production of high-quality finished goods. Darya-Varia always ensures the quality and safety of each product, so that all of its products are certified halal. All plant facilities owned by Darya-Varia have implemented the halal guarantee system. Blue Sphere Singapore Pte Ltd (BSSPL) owns 92.13% stake in Darya-Varia. For 45 years, Darya-Varia has continued to progress in providing high quality health facilities. Through the mission of "building a healthier Indonesia for everyone one person at a time", Darya-Varia is always committed to providing a variety of quality products with the right strategy for the health of the Indonesian people. DARYA VARIA
Company Leadership CH
Frequently Asked Questions Regarding PCI Pharma Services Top Executives and Leadership Team
Unlock more people and company data
